Primary source: Inspections and Compliance
Lisraya is now an FDA-approved therapeutic option for dermatomyositis in adults, altering treatment paradigms for this disease.
This approval is critical as it introduces the first effective oral treatment for a disease with historically limited options, positively impacting patient care and treatment outcomes for dermatomyositis.
Update product labeling to include Lisraya as the first oral treatment for dermatomyositis, ensuring that all marketing and educational materials reflect its approval and associated safety information.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Update product labeling to include Lisraya as the first oral treatment for dermatomyositis, ensuring that all marketing and educational materials reflect its approval and associated safety information.
The FDA has granted approval for Lisraya (brepocitinib), marking it as the first oral therapy available for managing dermatomyositis in adults. The approval provides a new option for patients who have historically had limited treatment alternatives. This drug works as a JAK/TYK2 inhibitor and is associated with specific safety warnings.
What changed: Lisraya is now an FDA-approved therapeutic option for dermatomyositis in adults, altering treatment paradigms for this disease.
Why it matters: This approval is critical as it introduces the first effective oral treatment for a disease with historically limited options, positively impacting patient care and treatment outcomes for dermatomyositis.
Practical implication: Update product labeling to include Lisraya as the first oral treatment for dermatomyositis, ensuring that all marketing and educational materials reflect its approval and associated safety information.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement enhanced surveillance and tracking of Salmonella cases linked to imported eggs, potentially increasing ICSR submissions related to these infections.
Compounding pharmacies must verify that all components used in injectable drugs are suitable for their intended use and discontinue the use of any glutathione labeled for dietary supplement purposes, particularly if sourced from Medisca.
Review and update internal compliance and reporting workflows to align with the FDA's reporting requirements for the latest oncology product approvals.
Cattle producers must administer Bimectin injection within specified timelines (24 hours post-birth, at castration, or on wound appearance) and observe a 35-day withdrawal period before slaughter to prevent drug residues in food.
